Aggressive Chemotherapy and the Selection of Drug Resistant Pathogens

PLoS Pathogens

Volumn 9, Issue 9, 2013, Pages

  Huijben, Silvie ^a,d   Bell, Andrew S ^a   Sim, Derek G ^a   Tomasello, Danielle ^a,e   Mideo, Nicole ^a   Day, Troy ^b   Read, Andrew F ^a,c  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b QUEEN S UNIVERSITY   (Canada)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRIMETHAMINE; ANTIMALARIAL AGENT;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BODY MASS; CELL DENSITY; CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REGIMEN; FEMALE; MALARIA; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PARASITE TRANSMISSION; WEIGHT REDUCTION; ANIMAL; BIOLOGICAL MODEL; BLOOD; C57BL MOUSE; CELL CLONE; DRUG EFFECTS; DRUG RESISTANCE; ERYTHROCYTE; GENETIC SELECTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; PARASITE IDENTIFICATION; PARASITOLOGY; PATHOGENICITY; PLASMODIUM CHABAUDI; VIRULENCE;

ANIMALS; ANTIMALARIALS; CLONE CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ERYTHROCYTES; FEMALE; MALARIA; MICE, INBRED C57BL; MODELS, BIOLOGICAL; PARASITE EGG COUNT; PLASMODIUM CHABAUDI; PYRIMETHAMINE; SELECTION, GENETIC; VIRULENCE;

EID: 84884682077     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003578     Document Type: Article

References (52)

1. Fleming A (1964) Penicillin. Nobel Lectures, Physiology or Medicine 1942-1962. Amsterdam: Elsevier Publishing Company.
2. World Health Organization (2011) World malaria report 2011. Geneva, Switzerland. Available: http://www.who.int/malaria/world_malaria_report_2011.
3. World Health Organization (2012) The evolving threat of antimicrobial resistance: options for action. Available: http://whqlibdoc.who.int/publications/2012/9789241503181_eng.pdf.
4. World Health Organization (2011) Global tuberculosis control: WHO report 2011. Available: http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf.
5. Deeks SG, Smith M, Holodniy M, Kahn JO, (1997) HIV-1 protease inhibitors- A review for clinicians. J Am Med Assoc 277: 145-153.
6. Stratton CW, (2003) Dead bugs don't mutate: Susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 9: 10-16.
7. Martinez MN, Papich MG, Drusano GL, (2012) Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 56: 2795-2805.
8. Drusano GL, Liu W, Brown DL, Rice LB, Louie A, (2009) Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus. J Infect Dis 199: 219-226.
9. Drusano GL, (2004) Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'. Nat Rev Microbiol 2: 289-300.
10. Condra JH, Emini EA, (1997) Preventing HIV-1 drug resistance. Sci Med 4: 14-23.
11. Roberts JA, Kruger P, Paterson DL, Lipman J, (2008) Antibiotic resistance- What's dosing got to do with it? Crit Care Med 36: 2433-2440.
12. zur Wiesch PA, Kouyos R, Engelstadter J, Regoes RR, Bonhoeffer S, (2011) Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect Dis 11: 236-247.
13. Rapoff MA (2010) Adherence to pediatric medical regimens, Second Edition. Dordrecht: Springer. 231 p.
14. Crow JF, Kimura M (1970) An introduction to population genetics theory. New York: Harper and Row. 591 p.
15. Read AF, Day T, Huijben S, (2011) The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc Natl Acad Sci USA 108: 10871-10877.
16. de Roode JC, Culleton R, Bell AS, Read AF, (2004) Competitive release of drug resistance following drug treatment of mixed Plasmodium chabaudi infections. Malar J 3: 33.
17. Gerrish PJ, Lenski RE, (1998) The fate of competing beneficial mutations in an asexual population. Genetica 102-3: 127-144.
18. Miralles R, Gerrish PJ, Moya A, Elena SF, (1999) Clonal interference and the evolution of RNA viruses. Science 285: 1745-1747.
19. Read AF, Taylor LH, (2001) The ecology of genetically diverse infections. Science 292: 1099-1102.
20. Hastings IM, (1997) A model for the origins and spread of drug-resistant malaria. Parasitology 115: 133-141.
21. Mackinnon MJ, Hastings IM, (1998) The evolution of multiple drug resistance in malaria parasites. Trans R Soc Trop Med Hyg 92: 188-195.
22. Hastings IM, D'Alessandro U, (2000) Modelling a predictable disaster: The rise and spread of drug-resistant malaria. Parasitol Today 16: 340-347.
23. Hastings IM, (2006) Complex dynamics and stability of resistance to antimalarial drugs. Parasitology 132: 615-624.
24. Mackinnon MJ, (2005) Drug resistance models for malaria. Acta Trop 94: 207-217.
25. Lipsitch M, Samore MH, (2002) Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis 8: 347-354.
26. Bell AS, Huijben S, Paaijmans KP, Sim DG, Chan BHK, et al. (2012) Enhanced transmission of drug-resistant parasites to mosquitoes following drug treatment in rodent malaria. PLoS One 7: e37172.
27. Wargo AR, Huijben S, de Roode JC, Shepherd J, Read AF, (2007) Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc Natl Acad Sci USA 104: 19914-19919.
28. Huijben S, Nelson WA, Wargo AR, Sim DG, Read AF, (2010) Chemotherapy, within-host ecology and the fitness of drug-resistant malaria parasites. Evolution 64: 2952-2968.
29. Geli P, Laxminarayan R, Dunne M, Smith DL, (2012) "One-Size-Fits-All"? Optimizing treatment duration for bacterial infections. PLoS One 7: e29838.
30. Aarestrup F, (2012) Get pigs off antibiotics. Nature 486: 465-466.
31. Scalera NM, File TM Jr, (2007) How long should we treat community-acquired pneumonia? Curr Opin Infect Dis 20: 177-181.
32. el Moussaoui R, de Borgie C, van den Broek P, Hustinx WN, Bresser P, et al. (2006) Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. Br Med J 332: 1355-1358.
33. Kaki R, Elligsen M, Walker S, Simor A, Palmay L, et al. (2011) Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother 66: 1223-1230.
34. Pugh R, Grant C, Cooke RPD, Dempsey G, (2011) Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev pp. Cd007577.
35. Karageorgopoulos DE, Valkimadi PE, Kapaskelis A, Rafailidis PI, Falagas ME, (2009) Short versus long duration of antibiotic therapy for bacterial meningitis: a meta-analysis of randomised controlled trials in children. Arch Dis Child 94: 607-614.
36. Molyneux E, Nizami SQ, Saha S, Huu KT, Azam M, et al. (2011) 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study. Lancet 377: 1837-1845.
37. Esposito S, Tagliabue C, Picciolli I, Semino M, Sabatini C, et al. (2011) Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. Respir Med 105: 1939-1945.
38. Lipsitch M, Levin BR, (1997) The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 41: 363-373.
39. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL, (2007) The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: A new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother 51: 744-747.
40. Drusano GL, Liu W, Fregeau C, Kulawy R, Louie A, (2009) Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob Agents Chemother 53: 2266-2273.
41. Handel A, Margolis E, Levin BR, (2009) Exploring the role of the immune response in preventing antibiotic resistance. J Theor Biol 256: 655-662.
42. Luciani F, Sisson SA, Jiang HL, Francis AR, Tanaka MM, (2009) The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 106: 14711-14715.
43. Wootton JC, Feng XR, Ferdig MT, Cooper RA, Mu JB, et al. (2002) Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 418: 320-323.
44. Talisuna AO, Bloland P, D'Alessandro U, (2004) History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 17: 235-254.
45. Gatenby RA, (2009) A change of strategy in the war on cancer. Nature 459: 508-509.
46. Gatenby RA, Silva AS, Gillies RJ, Frieden BR, (2009) Adaptive therapy. Cancer Res 69: 4894-4903.
47. Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, et al. (2012) Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res 72: 6362-6370.
48. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R, (2008) Accelerated evolution of resistance in multidrug environments. Proc Natl Acad Sci USA 105: 13977-13981.
49. Pena-Miller R, Laehnemann D, Jansen G, Fuentes-Hernadez A, Rosenstiel P, et al. (in press) When the most potent combination of antibiotics selects for the greatest bacterial load: the smile -frown transition. PLoS Biol 11: e1001540.
50. Mideo N, Barclay VC, Chan BHK, Savill NJ, Read AF, et al. (2008) Understanding and predicting strain-specific patterns of pathogenesis in the rodent malaria Plasmodium chabaudi. Am Nat 172: E214-E238.
51. White NJ, (2008) Qinghaosu (Artemisinin): The price of success. Science 320: 330-334.
52. Schneider P, Chan BHK, Reece SE, Read AF, (2008) Does the drug sensitivity of malaria parasites depend on their virulence? Malar J 7: 257.